Pediatric type 1 diabetes

Early treatment with the anti-CD3 monoclonal antibody teplizumab may help to preserve β-cell function in children and adolescents with newly diagnosed type 1 diabetes, results of the phase 3 PROTECT study show.

Data from the DPV cohort show a reduced risk for severe hypoglycemia and diabetic ketoacidosis among children and young people with type 1 diabetes using continuous glucose monitoring rather than self-monitored blood glucose.

The Tandem Control-IQ system delivers improved glucose control versus standard care in children with type 1 diabetes aged between 2 and 6 years and can be initiated virtually, report researchers.

Two linked randomized trials published in JAMA support a role for verapamil, but not for intensive glycemic control, to slow C-peptide decline in children with newly diagnosed type 1 diabetes.

“Almost no one” who is islet autoantibody negative at age 10 years despite a high familial risk for type 1 diabetes will develop clinical diabetes by the age of 18, report researchers.

Click through to read more on this announcement

Nearly half of all cases of type 1 diabetes occurring annually in children and adolescents may go undiagnosed, especially in low- and middle-income countries, show the results of a modeling study.

Testing for autoantibodies to endogenous insulin in addition to regular autoantibody screening can increase the proportion of children with an autoimmune classification for newly diagnosed type 1 diabetes, UK research suggests.

Analysis of childhood type 1 diabetes diagnoses across 13 countries indicates that the conditions created by the COVID-19 pandemic worsened pre-existing increasing trends in ketoacidosis at diagnosis.

Among adolescents with type 1 diabetes, those with better self-care are more likely to have favorable glycated hemoglobin trajectories into early adulthood, study findings suggest.

Starting young people on closed-loop insulin delivery within 21 days after type 1 diabetes diagnosis does not slow the decline in their C-peptide levels over the next 12 months, report the CLOuD investigators.

Improved glycemic control with hybrid closed-loop insulin delivery may facilitate the typical neurodevelopmental changes that occur during adolescence for those with type 1 diabetes, suggests a proof-of-concept trial.

Reducing the cutoffs of commonly used depression screening measures may increase the sensitivity for detecting depression in adolescents with type 1 diabetes, US study findings indicate.

Most parents of children starting continuous glucose monitoring soon after their type 1 diabetes diagnosis find virtual initiation to be convenient and effective, shows a small study.

Researchers have found that the early morning psychosocial state of adolescents and young adults with type 1 diabetes explains a proportion of their daily variance in time in range.

Testing high-risk children for islet autoantibodies twice, at the ages of 2 and 6 years, is sufficient to predict the majority of clinical cases of type 1 diabetes diagnosed by the age of 15, a study suggests.

Children and adolescents using an advanced hybrid closed-loop system for type 1 diabetes can tolerate an unannounced snack containing 20 g of carbohydrate without excessive blood sugar fluctuations, Italian researchers report.

The Omnipod 5 closed-loop, tubeless insulin delivery system has achieved good results in young children with type 1 diabetes over 12 months, with no cases of severe hypoglycemia or diabetic ketoacidosis recorded.

Ultra-rapid lispro gives equivalent overall glycemic control to standard lispro, and is significantly better for some postprandial measurements in children with type 1 diabetes, shows the PRONTO-Peds trial.

The iLet bionic pancreas closed-loop insulin delivery system provides good glucose control without the need for the user to count carbohydrates, show findings from the pivotal trial.